BRIEF—Recipharm acquires GenIbet to bolster biologics offering

Sweden-headquartered contract development and manufacturing organization Recipharm today announced the acquisition of GenIbet, a Portuguese CDMO, specializing in the manufacture of biological clinical trial material and novel modalities such as viral vectors, RNA and microbiome.

The acquisition, financial terms of which were not disclosed, forms part of Recipharm’s strategy to grow in the Biologics market, with a particular focus on drug substance manufacturing of novel ATMPs.

GenIbet currently works with customer projects in the preclinical and Phase I stages and has a track record of developing novel production processes. Through its relationship with not-for-profit research organization Ibet, the CDMO offers deep scientific expertise and novel solutions where no established production route exists.

The deal will provide Recipharm with a platform from which to build its capabilities in new Biologics modalities, leveraging GenIbet’s expertise in viral vectors and vaccines.